NCT06773754View on ClinicalTrials.gov

Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Taken as 5 Days Per Week

NAActive, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

September 1, 2023

Study Completion Date

December 31, 2025

Conditions
Virally Suppressed People With HIV
Interventions
OTHER

Five-days-On and Two-days-Off

Take Fixed-Dose Combination of Bictegravir/Emtricitabine/Tenofovir alafenamide five days a week (Five-days-On and Two-days-Off)

Trial Locations (1)

100225

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER